Brii Biosciences Ltd (HKSE:02137)

HK$ 1.07 0.02 (1.9%) Market Cap: 782.15 Mil Enterprise Value: -1.80 Bil PE Ratio: 0 PB Ratio: 0.25 GF Score: 36/100

Half Year 2024 Brii Biosciences Ltd Earnings Call Transcript
Aug 20, 2024

HK$0.96 (-2.04%)

Earnings
Brii Biosciences Ltd AASLD Data Readout Investor Call Transcript
Nov 14, 2023
Brii Biosciences Ltd HBV R&D Day Transcript
Aug 24, 2023
Half Year 2023 Brii Biosciences Ltd Earnings Call Transcript
Aug 23, 2023

HK$2.79 (+0.72%)

Earnings
Brii Biosciences Ltd to Discuss VBI Deal and Corporate Update Call Transcript
Jul 06, 2023
Full Year 2022 Brii Biosciences Ltd Earnings Call Transcript
Mar 24, 2023

HK$5.03 (-2.33%)

Earnings
Half Year 2022 Brii Biosciences Ltd Earnings Call Transcript
Aug 24, 2022

HK$7.57 (-3.81%)

Earnings
Full Year 2021 Brii Biosciences Ltd Earnings Call Transcript
Mar 23, 2022

HK$10.84 (-4.24%)

Earnings
Brii Biosciences Ltd Business Update Call: HIV Ph 1 Study Status Transcript
Dec 14, 2021
Half Year 2021 Brii Biosciences Ltd Earnings Call Transcript
Aug 27, 2021

HK$37.6 (+1.21%)

Earnings

Half Year 2022 Brii Biosciences Ltd Earnings Call Transcript

Aug 24, 2022 / 12:30PM GMT

Release Date Price: HK$7.57 (-3.81%)

Transcript

Chris Fang

Director of Investor Relations - Brii Biosciences Limited

Good day everyone. Thank you for (technical difficulty) half of 2022 Earnings Conference Call. Our interim results announcement can be found on the investor relations section of our company website. (Operator Instructions) Please be advised that todays conference is recorded. This is Chris Fang, Director of Investor Relations of the company.

Joining us today on the call Brii Bios executive team management team are Dr. Zhi Hong, Chairman and CEO, Mr. Rogers Luo, President and General Manager of Greater China, Dr. Li Yan, Chief Medical Officer, Dr. Susannah Cantrell, our newly appointed Chief Business Officer, and Dr. Ankang Li, Chief Financial & Strategy Officer.

Dr. Hong will first provide an overview covering our strategic pipeline and organizational development, followed by Mr. Luo, who will provide an update on our recently and commercialized COVID-19 therapy and our priorities in China. Dr. Yan will then review overall R&D structure and our U.S. priorities. Dr. Cantrell will review our business development

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.